You are here

FDA Accepts Application for IV Immunoglobulin

Approval review scheduled for late 2016

The FDA has accepted for review a biologics license application for IVIG-SN (human normal immunoglobulin G for intravenous administration, Green Cross Corporation) intended for the treatment of primary immunodeficiency diseases (PIDs).

The Prescription Drug User Fee Act (PDUFA) date for the FDA to complete its review has been scheduled for the fourth quarter of 2016.

IVIG-SN demonstrated positive results in a phase 3 study in patients with PID, meeting its primary endpoint of no acute serious bacterial infections. These results, included in the FDA submission, were well under the requirement specified by the agency’s guidance of no more than one acute serious bacterial infection per patient-year.

PIDs are inherited genetic disorders that cause individuals to have a deficient or absent immune system because of either a lack of necessary antibodies or a failure of these antibodies to function properly. PID patients are vulnerable to infections and are more likely to experience complications from those infections. According to the World Health Organization, there are more than 150 different presentations of PID.

Headquartered in South Korea, Green Cross Corporation is the largest plasma-protein product manufacturer in Asia.

Source: Pipeline Review; January 25, 2016.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs